Opioid overdose after extended-release buprenorphine injection: a case report.  Isenberg R.  Am J Drug Alcohol Abuse. 2024 Jan 22:1-2. doi: 10.1080/00952990.2023.2292011. Epub ahead of print. PMID: 38252881. https://www.tandfonline…

The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.  Barnett A, Pienaar K, Lubman DI, Arunogiri S, Phan V, Hayes V, Lintzeris N, Savic M.  Int J Drug Poli…

Micro-dosing with buprenorphine when switching from full agonists (methadone, SR-morphine) to buprenorphine treatment in opioid agonist-assisted treatment programmes in Slovenia Miha Lavre, and Andrej Kastelic Heroin Addiction and Related Clinical…

Case report: Successful induction of buprenorphine in medically complex patients concurrently on opioids: a case series at a tertiary care center.  Shelton T, Nama S, Hall O, Williams M.  Front Pharmacol. 2024 Mar 8;15:1335345. doi: 10.3…

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.  Farrell M, Shahbazi J, Chambers M, Byrne M, Gholami J, Zahra E…

Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.  Johnson B, Monwell B, Capusan AJ.  Harm Reduct J…